Chromocell Therapeutics Corp financial data

Symbol
CHRO
Location
685 Us Highway One, North Brunswick, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.88 M shares
Common Stock, Shares, Outstanding 5.77 M shares
Common Stock, Value, Issued 578 USD
Weighted Average Number of Shares Outstanding, Basic 4.69 M shares +322%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 467 K USD +151%
General and Administrative Expense 788 K USD +64.9%
Operating Income (Loss) -1.93 M USD -111%
Nonoperating Income (Expense) -628 K USD -1109%
Net Income (Loss) Attributable to Parent -2.56 M USD -165%
Earnings Per Share, Basic -0.55 USD/shares +36.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.8 M USD
Assets, Current 4.03 M USD
Assets 4.03 M USD
Accrued Liabilities, Current 494 K USD
Liabilities, Current 2.9 M USD
Liabilities 2.9 M USD
Retained Earnings (Accumulated Deficit) -16.1 M USD
Stockholders' Equity Attributable to Parent 1.13 M USD
Liabilities and Equity 4.03 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.99 M USD -1049%
Net Cash Provided by (Used in) Financing Activities 5.67 M USD +3295%
Common Stock, Shares Authorized 200 M shares
Common Stock, Shares, Issued 5.77 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.77 M USD +7656%
Additional Paid in Capital 17.2 M USD